Search results for "thrombocytopenia"

showing 10 items of 76 documents

Antimicorbial prophylaxis in patients with immune thrombocytopenia treated with rituximab:a retrospective analysis

2019

anticmirbial prophylaxisimmune thrombocytopeniaanti-CD20 immunesuppressive therapy
researchProduct

Sepsis in head and neck cancer patients treated with chemotherapy and radiation: literature review and consensus

2015

Abstract: The reporting of infection/sepsis in chemo/radiation-treated head and neck cancer patients is sparse and the problem is underestimated. A multidisciplinary group of head and neck cancer specialists from Italy met with the aim of reaching a consensus on a clinical definition and management of infections and sepsis. The Delphi appropriateness method was used for this consensus. External expert reviewers then evaluated the conclusions carefully according to their area of expertise. The paper contains seven clusters of statements about the clinical definition and management of infections and sepsis in head and neck cancer patients, which had a consensus. Furthermore, it offers a revie…

cancer patientpathogenesipositron emission tomographyhealthcare associated infectionSettore MED/06 - Oncologia Medicapatient monitoringradiodiagnosimedicine.medical_treatmentChemotherapy; Head and neck cancer; Radiotherapy; SepsisthrombocytopeniaReviewblood cultureorgan injurymedical terminologyMedicineHead and neck cancermetabolic acidosiC reactive proteinHead and Neck Neoplasmmedical specialisttreatment withdrawalconsensus developmentHematologyclinical practicesystemic inflammatory response syndromeItalyOncologyHead and Neck Neoplasmslaboratory testthrombocytosichemically induced/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingchemotherapy; head and neck cancer; radiotherapy; sepsis; oncology; hematology; geriatrics and gerontologyorgan perfusionhospitalizationHumansepsis Head and Neck Neoplasmmedicine.medical_specialtySettore MED/17 - Malattie InfettiveSepsibacterium culturediagnostic approach routefluorodeoxyglucosecancer chemotherapySepsisSDG 3 - Good Health and Well-beingSepsiscancer radiotherapyfollow upChemotherapyHumansinfection riskIntensive care medicineprocalcitonin antimicrobial therapyChemotherapyRadiotherapybusiness.industrydisease predispositionHead and neck cancerlactic acidChemotherapy; Head and neck cancer; Radiotherapy; Sepsis; Humans; Italy; Head and Neck Neoplasms; Sepsis; Hematology; Oncology; Geriatrics and Gerontologymedicine.diseasemortalityDelphi studyRadiation therapyinflammationincidencehyperglycemiaHuman medicineGeriatrics and Gerontologybusiness
researchProduct

Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study

2020

Salvatrice Mancuso,1 Melania Carlisi,1 Nicola Serra,2,3 Mariasanta Napolitano,1 Simona Raso,3 Ugo Consoli,4 Roberto Palazzolo,5 Maria Rosa Lanza Cariccio,6 Sergio Siragusa1 1Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, Palermo, Italy; 2Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples, Italy; 3Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy; 4UOC Ematologia ARNAS Garibaldi, Catania, Italy; 5UOS Ematologia, Asst Valtellina e Alto Lario, Sondrio, Italy; 6Dipartimento Oncologico, La Maddalena,…

immunogeriatricsaging.immuno-geriatricsitp treatmentlcsh:RC633-647.5agingImmunogeriatriclcsh:Diseases of the blood and blood-forming organsSettore MED/15 - Malattie Del SangueJournal of Blood Medicinetpo-receptor agonistprimary immune thrombocytopenia (itp)ITPPrimary immune thrombocytopeniaOriginal ResearchJournal of Blood Medicine
researchProduct

Use of low dose of rFVIIa (recombinant Factor VII activated) to control late bleeding after percutaneous dilational tracheostomy

2019

Key Clinical Message In our case, the use of a low intravenous bolus dose of rFVIIa (recombinant factor VII activated; 15‐20 mcg/kg) was effective and uneventful in controlling late postprocedural PDT bleeding associated with thrombocytopenia that cannot be corrected and after all other treatments failed.

lcsh:MedicineCase ReportCase Reports030204 cardiovascular system & hematologyIntravenous boluslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawActivated factor VIIpercutaneous tracheostomyMedicinepostoperatory bleedinglcsh:R5-920activated factor VIIFactor VIIbusiness.industrylcsh:RLow doserFVIIaGeneral MedicineThrombocytopeniaPercutaneous dilational tracheostomychemistry030220 oncology & carcinogenesisAnesthesiaPercutaneous tracheostomyRecombinant DNAlcsh:Medicine (General)businessClinical Case Reports
researchProduct

The Value of a Complete Blood Count (CBC) for Sepsis Diagnosis and Prognosis.

2021

Sepsis represents an important global health burden due to its high mortality and morbidity. The rapid detection of sepsis is crucial in order to prevent adverse outcomes and reduce mortality. However, the diagnosis of sepsis is still challenging and many efforts have been made to identify reliable biomarkers. Unfortunately, many investigated biomarkers have several limitations that do not support their introduction in clinical practice, such as moderate diagnostic and prognostic accuracy, long turn-around time, and high-costs. Complete blood count represents instead a precious test that provides a wealth of information on individual health status. It can guide clinicians to early-identify …

lymphocytesMedicine (General)medicine.medical_specialtyAnemiaClinical BiochemistryContext (language use)thrombocytopeniaReviewlymphocyteRBClaw.inventionSepsissepsisR5-920neutrophilslawGlobal healthMedicineIntensive care medicinemedicine.diagnostic_testbusiness.industryComplete blood countneutrophilEmergency departmentCPDmedicine.diseaseIntensive care unitanemiaSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicamonocyteBiomarker (medicine)biomarkersepsibusinessmonocytesCBCDiagnostics (Basel, Switzerland)
researchProduct

PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC

2021

The current COVID-19 pandemic requires revisiting our current approach to major blood disorders, including ITP (Immune Thrombocytopenia), stirring  up the production of several disease-specific practical guidelines. This report describes an updated version of consensus-based practical guidelines on the management of ITP, adapted to the Italian health system and social context.  It highlights the role of the hematologist in offering guidance for choosing differentiated approaches in relation to specific circumstances and is intended to provide them with a useful tool for sharing the decision-making process with their patients.
 Probably, the greatest risk to avoid for a patient with sus…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industrymedicine.medical_treatmentSplenectomySocial environmentHematology030204 cardiovascular system & hematologyImmune thrombocytopenia03 medical and health sciencesTherapeutic approach0302 clinical medicineInfectious DiseasesBlood Disorderhemic and lymphatic diseasesPandemicmedicine030212 general & internal medicineHematologistIntensive care medicinebusinessMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia

2018

Background: Intravenous immunoglobulin (IVIG) IQYMUNE® is a highly purified 10% IVIG that was assessed using the new stringent definition of response described in the revised guideline on the clinical investigation of IVIG. The efficacy and the safety of IQYMUNE® were investigated in adult patients with chronic primary immune thrombocytopenia (ITP). Methods: In this phase III multinational, multicentre, prospective, uncontrolled, open-label, single-arm study, adult patients with a baseline platelet count < 30 × 10 9 /L were treated with IVIG 10% at a dose of 2 g/kg body weight administered over 2 consecutive days. The primary endpoint was Response over the study period and was defined accor…

medicine.medical_specialtyEuropean Medicines Agency guidelinesPlatelet countRenal functionHigh dose030204 cardiovascular system & hematologyGastroenterology03 medical and health sciencesIntravenous immunoglobulin; High dose; Immune thrombocytopenia; Response; European Medicines Agency guidelines; Platelet count; Bleeding assessment; Infusion rate0302 clinical medicineInfusion rateInternal medicinemedicineClinical endpointPlateletAdverse effectIntravenous immunoglobulinbiologybusiness.industryResponseGuidelineImmune thrombocytopeniaImmune thrombocytopenia030220 oncology & carcinogenesisConcomitantbiology.proteinBleeding assessmentOriginal ArticleAntibodybusinessJournal of Hematology
researchProduct

Safety and tolerability of omalizumab

2009

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody with proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post-marketing safety data. Analysis focuses on the risk of immune-system effects, hypersensitivity reactions, malignant neoplasia, parasitic in…

medicine.medical_specialtyImmunologyOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal HumanizedInfectionsImmunoglobulin EAnti-asthmatic AgentNeoplasmsInternal medicinemedicineHumansImmunology and AllergyAnti-Asthmatic AgentsAnaphylaxisAsthmaClinical Trials as Topicbiologybusiness.industryIncidence (epidemiology)Antibodies Monoclonalmedicine.diseaseThrombocytopeniaAsthmaAntibodies Anti-IdiotypicClinical trialTolerabilityImmunologybiology.proteinbusinessAnaphylaxismedicine.drugClinical &amp; Experimental Allergy
researchProduct

Diagnosis of Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical Score Based on Objective Features Identified by a …

2019

Background: Diagnosis of heparin-induced thrombocytopenia (HIT) is based on a composite of clinical likelihood and laboratory testing. We aimed to develop a diagnostic score derived from multivariate analysis of clinical features, including platelet count changes, prospectively recorded in patients with suspected HIT. Methods: This multinational observational study (ClinicalTrials.gov no. NCT00748839) included 2280 adult patients with suspected HIT: 1597 (derivation cohort) formed the basis for developing the scoring system, subsequently validated in 683 additional randomly selected patients (validation cohort). HIT was diagnosed by two independent adjudicators based on clinical features, l…

medicine.medical_specialtyMultivariate analysisbusiness.industryMajor traumamedicine.diseaseIntensive care unitlaw.inventionInformed consentlawInternal medicineHeparin-induced thrombocytopeniaGood clinical practiceMedicineObservational studybusinessProspective cohort studySSRN Electronic Journal
researchProduct

Quantitative and Qualitative Platelet Derangements in Cardiac Surgery and Extracorporeal Life Support

2021

Thrombocytopenia and impaired platelet function are known as intrinsic drawbacks of cardiac surgery and extracorporeal life supports (ECLS). A number of different factors influence platelet count and function including the inflammatory response to a cardiopulmonary bypass (CPB) or to ECLS, hemodilution, hypothermia, mechanical damage and preoperative treatment with platelet-inhibiting agents. Moreover, although underestimated, heparin-induced thrombocytopenia is still a hiccup in the perioperative management of cardiac surgical and, above all, ECLS patients. Moreover, recent investigations have highlighted how platelet disorders also affect patients undergoing biological prosthesis implanta…

medicine.medical_specialtyPlatelet disorderbiological prosthesisRESPIRATORY-FAILUREProsthesis Implantationlcsh:MedicinethrombocytopeniaReview030204 cardiovascular system & hematologyextracorporeal life supportExtracorporeallaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineCardiopulmonary bypassmedicinePlatelet030304 developmental biologyplateletUNFRACTIONATED HEPARIN0303 health sciencesCARDIOPULMONARY BYPASSbusiness.industrylcsh:RMEMBRANE-OXYGENATIONACTIVATED PLATELETSGeneral MedicineHypothermiaENDOTHELIAL-CELLSANTIBODY-FORMATIONCardiac surgeryinflammationCORONARY-ARTERY-BYPASSLife supportAORTIC-VALVE-REPLACEMENTCardiologyHEPARIN-INDUCED THROMBOCYTOPENIAmedicine.symptombusinesscardiac surgeryJournal of Clinical Medicine
researchProduct